Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

31 Jan 2019

Abstract excerpt

BACKGROUND: Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. METHODS: Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to May 2018 were enrolled in this study. PD-L1 expression in tumor cells (TC) and mismatch repair (MMR) were analyzed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Gastric Cancer Management and Outcomes
Share to Helicobacter pylori-related gastroenterology studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30704511
DOI: 10.1186/s40425-019-0514-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerPMID 30704511Read ↗

Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.Semantic proximity Read ↗

What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future PerspectivesSemantic proximity Read ↗

Alterations in Intratumoral Immune Response Before and Early-on-Treatment of Nivolumab in Unresectable Advanced or Recurrent Gastric CancerSemantic proximity Read ↗

Clinicopathological Features of Epstein-Barr Virus Infection, Microsatellite Instability, Tumor Mutation Burden and PD-L1 Status in Chinese Patients with Gastric CancerSemantic proximity Read ↗

Advanced gastric cancer: Current treatment landscape and future perspectives.Semantic proximity Read ↗

Clinicopathological features of Epstein-Barr virus infection, microsatellite instability, tumor mutation burden and PD-L1 status in Chinese patients with gastric cancerSemantic proximity Read ↗

Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.Semantic proximity Read ↗

Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer.Semantic proximity Read ↗

Current treatment and recent progress in gastric cancer.Semantic proximity Read ↗

Overview of Epstein–Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic OptionsSemantic proximity Read ↗

Real-World Genomic Landscape of Korean Gastric Cancer: Integrating Biomarker Associations and Clinical Outcomes in Metastatic Gastric Cancer.Semantic proximity Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.